Carvykti is prepared using the patient's own T-cells which are extracted from the blood, genetically modified in the laboratory, and then given back to the ...

13 февр. 2024 г. · Proposed: Ciltacabtagene autoleucel is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have ...

23 февр. 2024 г. · Cilta-cel is the first chimeric antigen receptor T-cell (CAR-T) therapy to receive a positive CHMP opinion for the treatment of this patient population, as ...

European Medicines Agency (EMA). Carvykti: EPAR - Product Information. [Available from: https://www.ema.europa.eu/en/documents/product-information/carvykti ...

CARVYKTI is authorized for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least 3 prior therapies, including ...

Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel) · Legend Biotech Corporation ( ...

25 мая 2023 г. · Cilta-cel received conditional marketing authorisation from the European Commission in May 2022, for the treatment of adults with relapsed and refractory ...

22 апр. 2024 г. · J&J. CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma ... Не найдено: epar | Нужно включить: epar

22 февр. 2024 г. · Ciltacabtagene autoleucel (Carvykti®, cilta-cel, JNJ-68284528) is a chimeric antigen receptor T-cell (CAR-T) therapy directed against B-cell ...

The products Abecma (idecabtagene vicleucel) and Carvykti (ciltacabtagene autoleucel) are genetically modified autologous T cell immunotherapies reprogramming a ...